André J. A. M . van der Ven et al lation to the kinetics of the parent compound and the Na-acetyl metabolite in healthy subjects (three slow, three fast acetylators).
M ethods

Subjects
Six Caucasians (four males, two females) ranging in age from 23 to 50 years (mean 34 years) participated after approval of the study by the Ethics Committee of our university hospital. Written informed consent was obtained from all participants. All subjects were drug-free and healthy by history, physical exam ina tion and routine biochemical assessment. An 800 ms dose of sulphamethoxazole was administered orally in two gelatine capsules on an empty stomach after an overnight fasting.
Sampling procedures
Blood samples were obtained by fingertip puncture at 1, 2, 4, 6, 8, 10, 12, 24, 32, 36 , and 48 h after drug administration. Plasma was separated immediately by centrifugation and stored at -20° C until analysis. Urine was collected over 96 h and three 5 ml aliquots were stored immediately at -20° C until analysis.
Acetylator phenotype
Volunteers were phenotyped using sulphadimidine as described previously [13] .
Chemicals SMX and Na-AcSMX were obtained from Hoffmann LaRoche, Mijdrecht, the Netherlands. NOH-SMX was obtained from Synthon BV, Nijmegen, the Netherlands. All other chemicals were of analytical purity and were obtained from commericial sources. jjg ml-1, respectively, in plasma and 0.10 pg ml-1 for all compounds in urine. The hydroxylamine metabo lite was stable in anaerobic plasma and urine.
Sample preparation
After thawing, the sample (100 pi) was diluted with 900 pi 0.33 M trichloroacetic acid, centrifuged at 3000 g, and the supernatant injected onto the column.
Data analysis
Renal clearances were calculated from urinary recov eries of the compounds (corrected for molecular weight) divided by the corresponding AUC values. Curve litting to a one compartment model with first order drug absorption was carried out using the Mediware'K computer program 15. AUC values were calcu lated using the linear trapezoidal rule with extrapolation to infinity using C(last)/k. Oral clear ance (CL0) of SMX and its mean residence time (MRT) were calculated by standard methods [14] .
Statistics
The Mann-Whitney test was used to compare results. Pearson correlation coefficients were calculated. Dif ferences were considered significant when P < 0.05.
R esults
Plasma concentrations and renal excretion rates of SMX, NOH-SMX and Na-AcSMX in a representative subject are shown in Figure 1 . Mean pharmacokinetic parameters are summarised in Table 1 .
The elimination half-life of SMX was 9.5 h while the half-lives of N4-AcSMX and NOH-SMX were 11.1 and 11.2 h, respectively (NS). The mean resi dence time of SMX was 14.0 h and those of N4-
Drug analysis
SMX and its metabolites were assayed by h.p.l.c. using a Spectra Physics SP8810 pump (Eindhoven, The Netherlands), a 757 Separations u.v. detector (Hendrik Ido Ambacht, The Netherlands) and a C 8 (5 um) column (Synthon, Nijmegen, The Netherlands) (250 mm x 4 mm i.d.). The mobile phase consisted of 45 ml of a mixture of 20 g orthophosphoric acid and 5 g tetramethylammonium chloride in 1 1 water, 45 ml dimethylformamide and 180 ml acetonitrile, adjusted to 1 1 with water. The mobile phase was degassed with helium before use. The How rate was 1.5 ml min-1. Detection was at 271 nm. The retention times of NOH-SMX, SMX, and N4-ACSMX were 8 .6 , 10.1 and 13.3 min, respectively, and the chromatographic peaks were identified using authentic standards. Intraand interday variation in the assay of both samples and standards was <5%. Quantitation limits, deter mined with a signal-to-noise ratio of 3, for SMX, N4-AcSMX, and NOH-SM were 0.0055, 0.01, and 0.01 1 h"1) 1.2 ± 0.2 ( 1.0-1.6 ) CLr (1 I r 1)  0.22 ± 0.05 (0.14-0.28)  2.45 ± 0.35 (1.91-2.97)  4.39 ± 0.91 (3.44-5.51)  /4e(°°) (%) 16.5 ± 5.5 (8.3-23.4) 46.2 ± 6.6 AcSMX and NOH-SMX formed from SMX were 5.5 and 5.1 h, respectively. The urinary recoveries of parent drug and metabo lites were similar in all subjects. Sulphamethoxazole accounted for 16.5 ± 5.5% (percentage ± s.d.) of the dose, N4-AcSMX, for 46.2 ± 6 .6 %, and NOH-SMX, for 2.4 ± 0.8%. Three subjects acetylated sulphadimidine rapidly and three slowly. Renal excretion of NOH-SMX accounted for 1.9 ± 0.9% of the dose of SMX in the slow acetylators and 2.8 ± 0.3% in the fast acetylators. For N4-ACSMX, the values were 48 ± 6 % and 44 ± 8 %, respectively.
4-»
The clearance (metabolic-and renal clearance) of SMX was 1.21 ± 0.21 1 h_l. The mean renal clearance of SMX was 0.22 ± 0.05 1 h" 1, which differed significantly from that of N4-ACSMX (2.45 ± 0.35 1 h"1) and NOH-SMX (4.39 ±0.91 1 h r1) (paired /-test, P < 0.05). The renal clearance of SMX but not of its metabolites correlated with the urine pH (SMX, r = 0.91, all samples).
Discussion
Metabolism
After a single 800 mg oral dose of sulphamethoxa zole, the renal excretion of SMX, Na-AcSMX, and NOH-SMX accounted for 65% of the dose. The oral clearance of SMX (1.2 1 h_l) was much greater than its renal clearance (0.2 1 h_l). The fate of 35% of the dose is unknown.
The hydroxylamine metabolite accounted for 2.4% of the recovered dose of SMX, a figure in agreement with those reports by others [6 , 9] . Since NOH-SMX is unstable and can be oxidised to nitroso derivates |15J, it is possible that its urinary recovery is less than the amount formed in the liver. However, under physiological conditions glutathione prevents the auto oxidation of NOH-SMX [15].
Mechanism of renal clearance
After glomerular filtration, SMX undergoes net pas sive reabsorption while data for N4-ACSMX when corrected for plasma binding indicate that this com pound undergoes net active excretion [16] . Urine flow and pH govern passive reabsorption and influence the renal excretion of SMX but not that of N4-ACSMX. This difference in excretion is discernable from respective excretion rate-time profiles. Thus, the excretion rate-time curve of N4-AC-SMX was smooth and parallel to the corresponding plasma concentration-time curve, while that of SMX had an irregular profile. The shape of the excretion rate-time profile of NOH-SMX was similar to that of N4-ACSMX and, in a separate experiment, it was shown that the excre tion of NOH-SMX is not dependent on urine pH (data not shown). This suggests that NOH-SMX undergoes limited passive tubular reabsorption. The high renal clearance rates of N4-ACSMX and NOH-SMX com pared with that of SMX are associated with similar apparent half-lives.
Acetyl at or pheno typ e
A previous study indicated that SMX clearance is unrelated to acetylator phenotype [16] , and we now show that the excretion of N4-ACSMX is similar in both fast and slow acetylators of sulphadimidine. Overrepresentation of the slow acetylator phenotype has been reported in patients with sulphonamide hypersensitivity reactions [12] . Thus, it was sug gested that in slow acetylators more of the parent drug may be available for metabolism by cytochrome P450 to the hydroxylamine metabolites [12] . How ever, our data do not indicate an increased hydroxy lamine formation in slow sulphadimidine acetylators, although the number of subjects studied was limited.
This study has documented the formation and renal excretion of the N4-acetyl and hydroxylamine metabolites of sulphamethoxazole in healthy subjects.
